Bayer (FRA:BAYN) has been assigned a €77.00 ($89.53) target price by equities researchers at Goldman Sachs Group in a research note issued to investors on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s target price would indicate a potential upside of 25.12% from the stock’s current price.
Other research analysts have also issued reports about the stock. Kepler Capital Markets set a €70.00 ($81.40) target price on shares of Bayer and gave the company a “neutral” rating in a research note on Monday, March 25th. JPMorgan Chase & Co. set a €70.00 ($81.40) target price on shares of Bayer and gave the company a “neutral” rating in a research note on Thursday, March 28th. UBS Group set a €110.00 ($127.91) target price on shares of Bayer and gave the company a “buy” rating in a research note on Thursday, March 28th. Deutsche Bank set a €70.00 ($81.40) target price on shares of Bayer and gave the company a “neutral” rating in a research note on Monday, April 1st. Finally, DZ Bank reiterated a “neutral” rating on shares of Bayer in a research note on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the company. Bayer presently has an average rating of “Hold” and an average target price of €81.80 ($95.12).
FRA:BAYN traded down €0.67 ($0.78) during midday trading on Wednesday, reaching €61.54 ($71.56). The stock had a trading volume of 3,835,949 shares. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: Return on Investment (ROI)
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.